Investigation of the Reference Interval Values of Fasting Plasma Glucose, Blood Pressure, and Blood Lipids in the Longevity People Aged 90 Years Old and Above.
blood lipids
blood pressure
fasting plasma glucose
longevity
reference interval values
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
07
2021
accepted:
11
08
2021
entrez:
30
8
2021
pubmed:
31
8
2021
medline:
31
8
2021
Statut:
epublish
Résumé
To our knowledge, the normal fasting plasma glucose (FPG), blood pressure (BP), and blood lipids (BL) interval values have not been well-established in the longevity population. This study aims to provide a reference for the establishment of normal BP, FPG, and BL interval values in the longevity people in China. A total of 7417 people were selected from the natural longevity cohort in Guangxi, with an age range of 20-110 years old, including 7093 classified as the non-longevity (20-89 years old) (94.02%) and 324 classified as the longevity (≥90 years old) (5.98%); there were 4309 men (58.1%) and 3108 women (41.9%). FPG, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), and low-density lipoprotein (LDL-C) levels were defined as desirable levels when they were below the 75th percentile (P75), borderline levels from the 75th to 90th percentile (P75-P90), and high levels above P90; triglyceride (TG) levels above P90 were defined as high; and high-density lipoprotein cholesterol (HDL-C) levels below the 5th percentile (P5) were defined as low levels. The reference interval values of FPG in the longevity were as follows: desirable levels <6.15 mmol/L, borderline levels 6.15-7.45 mmol/L, high levels ≥7.45 mmol/L. Reference interval values of systolic blood pressure (SBP) were as follows: desirable levels <160.00 mmHg, borderline levels 160.00-174.50 mmHg, high levels ≥175.00 mmHg. DBP reference interval values were as follows: desirable levels <88.00 mmHg, borderline levels 88.00-90.00 mmHg, high levels ≥90.00 mmHg. TC reference interval values were as follows: desirable levels <5.59 mmol/L, borderline levels 5.59-6.45 mmol/L, high levels ≥6.45 mmol/L. LDL-C reference interval values were as follows: desirable levels <3.30 mmol/L, borderline levels 3.30-3.85 mmol/L, high levels ≥3.85 mmol/L. TG reference interval values were as follows: desirable levels <2.82 mmol/L, high levels ≥2.82 mmol/L. HDL-C reference interval values were as follows: low levels <0.80 mmol/L, desirable levels ≥0.80 mmol/L. The reference interval values of BP, FPG, and BL are different between the longevity population and the non-longevity population, and the interval values change with increasing age.
Identifiants
pubmed: 34456578
doi: 10.2147/DMSO.S327823
pii: 327823
pmc: PMC8387246
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3711-3718Informations de copyright
© 2021 Wang et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Aging Cell. 2017 Apr;16(2):329-338
pubmed: 28058805
J Intern Med. 2017 May;281(5):471-482
pubmed: 28345303
JAMA. 2003 Jan 8;289(2):187-93
pubmed: 12517229
Sci Total Environ. 2020 May 15;717:137191
pubmed: 32062280
Obesity (Silver Spring). 2010 Feb;18(2):333-9
pubmed: 19680230
Lancet. 1999 Aug 21;354(9179):652
pubmed: 10466675
Biogerontology. 2006 Oct-Dec;7(5-6):329-37
pubmed: 16953333
Exp Gerontol. 2009 Mar;44(3):136-60
pubmed: 19041386
Diabetes Metab. 2005 Dec;31 Spec No 2:5S27-5S34
pubmed: 16415763
Rev Saude Publica. 2005 Apr;39(2):163-8
pubmed: 15895133
Arteriosclerosis. 1983 Jan-Feb;3(1):64-76
pubmed: 6824497
J Hypertens. 2020 Jun;38(6):982-1004
pubmed: 32371787
Am J Physiol Heart Circ Physiol. 2012 Jan 1;302(1):H312-8
pubmed: 22003058
Geriatr Gerontol Int. 2017 Jul;17(7):1045-1047
pubmed: 28670849
Ageing Res Rev. 2015 Nov;24(Pt B):197-205
pubmed: 26304837
N Engl J Med. 2009 Dec 3;361(23):2252-60
pubmed: 19955525
Circulation. 2017 Jun 13;135(24):2357-2368
pubmed: 28432148
Pharmacol Rev. 2006 Sep;58(3):342-74
pubmed: 16968945
Pediatr Int. 2002 Dec;44(6):596-601
pubmed: 12421254
Int J Obes (Lond). 2019 Apr;43(4):782-789
pubmed: 30283076
Am J Cardiol. 2000 Nov 1;86(9):943-9
pubmed: 11053704
Bull World Health Organ. 2008 Aug;86(8):650-2
pubmed: 18797627
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693
Lancet. 1978 Oct 14;2(8094):807-9
pubmed: 81362
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3370-3378
pubmed: 30869791